MAVACAMTEN

Course overview

MAVACAMTEN IS A NOVEL, FIRST-IN-CLASS MOLECULE USED TO MANAGE AND TREAT PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM). IT IS CURRENTLY INDICATED FOR TREATING ADULTS WITH SYMPTOMATIC HEART FAILURE (NEW YORK HEART ASSOCIATION [NYHA] CLASS II AND III) SECONDARY TO OBSTRUCTIVE HCM TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS. MAVACAMTEN IS A SELECTIVE AND REVERSIBLE INHIBITOR OF THE CARDIAC MYOSIN ATPASE. THIS ACTIVITY REVIEWS THE INDICATIONS, MECHANISM OF ACTION, ADVERSE EFFECTS, AND MONITORING PROTOCOL OF MAVACAMTEN AS A NOVEL AGENT IN TREATING SYMPTOMATIC HEART FAILURE PATIENTS SECONDARY TO OBSTRUCTIVE HCM.